Mustafa Nevzat Pharmaceuticals

Report: Turkish manufacturers boost growth, niche products, biologics development

Wednesday, May 28, 2014

CPhI Worldwide’s Pharma Insights report on Turkey shows Turkish manufacturers moving beyond domestic market export has led to growth, niche products and biologics development. The comprehensive analysis of the Turkish pharma market was conducted among all major Turkish manufacturers, evaluating conditions for both foreign and domestic companies, and was compiled with the help of research partner Global Business Reports.

[Read More]

Amgen to acquire Mustafa Nevzat of Turkey

Wednesday, April 25, 2012

Amgen, a global biotech based in Thousand Oaks, Calif., will acquire 95.6% of shares in Mustafa Nevzat Pharmaceuticals (MN), a privately held Turkish pharmaceutical company, for approximately $700 million. The all-cash transaction will significantly expand Amgen’s presence in Turkey and the surrounding region, which are large, fast-growing, priority markets for Amgen.  

[Read More]